Global Proliferative Diabetic Retinopathy Market Size By Product Type (Anti-VEGF Agents, Corticosteroids), By Application (Hospitals, Clinics), By Geographic Scope And Forecast

Proliferative Diabetic Retinopathy Market Size And Forecast

Proliferative Diabetic Retinopathy Market size was valued at USD 2513.07 Million in 2022 and is projected to reach USD 9037.95 Million by 2030, growing at a CAGR of 17.35% from 2023 to 2030.

The rising incidence of diabetes, the increasing geriatric population base, and the rising numbers of diabetes-related loss of vision are anticipated to propel the growth of the Global Proliferative Diabetic Retinopathy Market. Overweight, changes in lifestyle, and intake of unhealthy foods are some of the factors that are likely to drive the market in the coming years. The Global Proliferative Diabetic Retinopathy Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors playing a substantial role in the market.

Global Proliferative Diabetic Retinopathy Market Definition

Since there are insufficient insulin hormones to metabolize blood sugar, diabetes is a chronic condition that never goes away. A diabetic patient who has an eye condition is said to have diabetic retinopathy. Proliferative The most severe form of diabetic eye damage is called diabetic retinopathy. The retina starts to develop new blood vessels at this stage. This process is called neovascularization. Frequently, the vitreous is bled into by these undesirable veins. If they bleed only a tiny bit, we only see a few small black floaters, but if they bleed a lot, eyesight may be completely obscured. PDR is a significant medical disorder that can impair both central and peripheral (side) vision if it is not promptly addressed.

It is identified using tests like fluorescein angiography and optical coherence tomography, and it is treated with intraocular steroid injection, laser therapy, and vitrectomy. The most prevalent symptoms of this disorder are blurred vision, dark or empty areas in the vision, fluctuating vision, impeded color vision, and loss of vision. The global proliferative diabetic retinopathy is classified as Non-Proliferative Diabetic Retinopathy( NPDR) and Proliferative Diabetic Retinopathy. Non-proliferative retinopathy is recognized as the early stage of DR when there is no abnormal enlargement of blood vessels (proliferation). NPDR deteriorates the walls of your retinal blood vessels.

This causes ‘micro aneurysms’ from the walls of the tiny blood vessels, starting to cause fluid and blood to leak into the retina. Proliferative Diabetic Retinopathy is the stage, where the previously damaged blood vessels have sealed off, enhancing the formation of new, abnormal blood vessels inside the retina, that are most prone to leaking blood and fluid into a clear, jelly-like particle that fills the central area of the eye. Diabetic retinopathy treatments depend on the severity of the condition and may include vitrectomy, intraocular injections, anti-VEGF drugs, and laser treatment. The disease can be resisted by managing diabetes, trying to control blood glucose levels, and paying enough attention to vision problems.

Global Proliferative Diabetic Retinopathy Market Overview

The rising incidence of diabetes, the increasing geriatric population base, and the growing incidence of diabetes-related vision loss are expected to dominate the growth Proliferative Diabetic Retinopathy Market. The increase in obesity, changes in lifestyle, and global intake of unhealthy foods are some of the factors that are expected to drive the market during the forecast period. Moreover, the general public has become more aware of the various treatment options and the privileges of early diagnosis of DR. As an outcome, advanced technological processes, and equipment, including improved ophthalmic diagnostic and surgical equipment, are now widely utilized leading to an increase in the growth of the Global Proliferative Diabetic Retinopathy Market.

The rising geriatric worldwide, as well as their elevated risk of chronic conditions such as diabetes, cardiovascular problems, and sleep problems, drive future growth to a considerable extent. The prospective restraints that hindered the entire market are a lack of reliable diagnosis, a lack of availability of skilled doctors and specialists, and adverse effects of treatment. Furthermore, surgical tools have improved precision, which increases the success rate of surgeries. As an outcome, the existence of such upgraded ophthalmic devices and systems has made possible medical and treatment procedures, which has a productive impact on industry growth.

However, issues and unfavorable consequences related to medications recommended to treat diabetic retinopathy may restrain market expansion. The future rise in diabetic retinopathy is driven by technological advancements in ophthalmic surgery, diagnostic, and treatment instruments throughout the anticipated period. Medical professionals can make better judgments because optical coherence tomography and other technologically sophisticated diagnostic tools provide higher-quality cross-sectional pictures. Additionally, surgical instruments are now more accurate, which raises the success rates of operations. Thus, the availability of such modernized ophthalmic gadgets has simplified diagnostic and therapeutic processes, favorably affecting the expansion of the market for proliferative diabetic retinopathy.

Global Proliferative Diabetic Retinopathy Market Segmentation Analysis

The Global Proliferative Diabetic Retinopathy Market is Segmented on the basis of Application Product Type, And Geography.

Proliferative Diabetic Retinopathy Market, By Product Type

• Anti-VEGF Agents
• Corticosteroids
• Other

Based on Product Type, The market is segmented into Anti-VEGF Agents, Corticosteroids, and Others. The Anti-VEGF agents are expected to grow the highest market during the forecasted period because this segment is needed to manage its dominance all throughout the forecast period, owing to the growing applications of anti-VEGF drugs including such Eylea, Macugen, Lucentis, and Avastin in the treatment of mild-to-moderate cases of diabetic retinopathy, which is among the main factors responsible for the segment’s growth.

Proliferative Diabetic Retinopathy Market, By Application

• Hospitals
• Clinics
• Others

Based on Application, The market is segmented into Hospitals, Clinics, and Others. Hospitals lead to the highest growth of global proliferative diabetic retinopathy during the forecasted period because the government funds the hospitals in the public healthcare system. As an outcome, these hospitals can manage to accept technologically advanced devices for ophthalmic surgeries, which profits growth of this segment.

Proliferative Diabetic Retinopathy Market, By Geography

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

On the basis of Regional Analysis, the Proliferative Diabetic Retinopathy Market is classified into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America is projected to be the highest-growing market over the forecasted period. Bayer AG is among the leading companies in the United States, and has captured the largest market share by introducing high-quality medications for diabetic retinopathy. As an outcome, the huge number of diabetes patients is anticipated to produce to growing market all across an entire region.

Key Players

The “Global Proliferative Diabetic Retinopathy Market” study report will provide valuable insight with an emphasis on the global market including some of the major players such as Merck KGaA, c, Intas Pharmaceuticals, Genentech Inc. (Roche Holdings), Valeant Pharmaceuticals International, Pfizer, Allergan Plc, Santen Pharmaceutical, Regeneron Pharmaceuticals

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players.

Key Developments

• In April 2023, Genentech, a subsidiary of the Roche Group, said that 30 abstracts at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, which will be held from April 23–27 in New Orleans, LA, would showcase new evidence for its marketed and experimental treatments.
• In September 2021, Intas Pharmaceuticals Ltd. (Intas) and Axantia Holding (Axantia), a significant Middle Eastern pharmaceutical organisation, have entered into an exclusive licence and supply agreement for Ranibizumab (a biosimilar to Lucentis®), which is manufactured by Pharma International Pharmaceutical & Chemical Manufacturing Co. Ltd. and Med City Pharmaceutical Industries. Axantia will register Ranibizumab, hold the marketing licence, and promote it in select regions, including Saudi Arabia, Jordan, Iraq, Lebanon, and the GCC nations. A biosimilar of Lucentis® that Intas has created is now undergoing a Phase III worldwide trial in preparation for submission to the EMA and the US, among other important nations.

Ace Matrix Analysis

The Ace Matrix provided in the report would help to understand how the major key players involved in this industry are performing as we provide a ranking for these companies based on various factors such as service features & innovations, scalability, innovation of services, industry coverage, industry reach, and growth roadmap. Based on these factors, we rank the companies into four categories as Active, Cutting Edge, Emerging, and Innovators.

Market Attractiveness

The image of market attractiveness provided would further help to get information about the region that is majorly leading in the Global Proliferative Diabetic Retinopathy Market. We cover the major impacting factors that are responsible for driving the industry growth in the given region.

Porter’s Five Forces

The image provided would further help to get information about Porter’s five forces framework providing a blueprint for understanding the behavior of competitors and a player’s strategic positioning in the respective industry. Porter’s five forces model can be used to assess the competitive landscape in the Global Proliferative Diabetic Retinopathy Market, gauge the attractiveness of a certain sector, and assess investment possibilities.

Report Scope

Top Trending Reports

Research Methodology of Market Research